An observational study in Missed Abortion, sponsored by Dr.Dalia Mohammed Al Sayed Zaki. Status unknown at 1 site in Egypt. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-20.
Sponsored by Dr.Dalia Mohammed Al Sayed Zaki · Observational
Aim of study Compare the success rate of misoprostol with versus without letrozole as a pretreatment for medical termination of pregnancy during the first trimester.
Hypothesis:
Letrozole value as a pre-treatment medication for misoprostol in induction of abortion during the first trimester.
Research question:
Will letrozole- misoprostol protocol give better results than misoprostol- alone protocol in induction of abortion during the first trimester?
Aim of the Work
Compare the success rate of misoprostol with versus without letrozole as a pretreatment for medical termination of pregnancy during the first trimester.
Hypothesis:
Letrozole value as a pre-treatment medication for misoprostol in induction of abortion during the first trimester.
Research question:
Will letrozole- misoprostol protocol give better results than misoprostol- alone protocol in induction of abortion during the first trimester?
Primary outcome:
Complete abortion (complete expulsion of products of conception with no need for curettage) within one week from the first dose of misoprostol.
Secondary outcome:
53 studies on the registry are indexed under Abortion, Missed; 10 are open to participants now.
Browse Abortion, Missed studies →This is the only study on the registry with Dr.Dalia Mohammed Al Sayed Zaki as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Study Settings:
This clinical trial will be conducted in department of obstetrics and gynecology at Zagazig General Hospital during the period between January 2019 and June 2019.
Study Population:
The patients will be recruited from women attending outpatient clinic of obstetrics or the emergency room of Zagazig General Hospital.
Exclusion criteria:
Group (A): A participant will receive three tablets of letrozole (Letrozole®, Technopharma) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start
Device: Letrozole misoprostol
Group (B): A participant will receive three tablets of placebo as a single dose on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start
Drug: Misoprostol, placebo
Letrozole give pretreatment of abortion by misoprostol
Give placebo pretreatment of abortion by misoprostol
Complete abortion
Complete abortion (complete expulsion of products of conception with no need for curettage) within one week from the first dose of misoprostol.
Time frame: 1week
Plan to share: No
This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.